BIA Separations, recently acquired by Sartorius, develops and manufactures market-leading CIM® monolithic chromatographic columns for purification and analysis of large biomolecules, such as viruses, plasmids and mRNA, which are applied in cell and gene therapies. BIA's technology for manufacturing-scale purification is already used in production of the first commercialized advanced therapeutics; BIA also has a keen presence with novel drug candidates in the clinical pipeline. Expecting continued strong double-digit sales growth over the next few years, BIA earned sales revenue of approx. 25 million Euros in 2020, contributing to Sartorius' Bioprocess Solutions, part of the Sartorius Group.
For the past 20 years, genOway has aimed to improve the predictability and reliability of preclinical data by designing models of high physiological relevancy to best meet researchers’ needs. With a catalog of humanized immune checkpoint mouse models, and mice featuring the human immune system, genOway possesses a broad set of tools to help decipher the mechanism of action as well as the efficacy and safety of drugs targeting the immune system. Additionally, genOway owns strong intellectual property rights, combining patents and licensing agreements, enabling the company to provide end users the necessary freedom to operate.